2016 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
04/06/16Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Board
MISSISSAUGA, ON, April 6, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has received Health Canada approvals for SD Cream and AD Cream (also known as Dermadexin and Pruridexin). Both products were approved in Canada by the Natural and Non-Prescription Health Products Directorate. In addition European approval of Helioclin® Pruritus SD Cream (also known as Pruridexin) was achieved. Helioclin® Dermatitis SD Cream (also know... 
Printer Friendly Version
04/05/16Cipher Pharmaceuticals announces Canadian launch of Beteflam™
Represents Fourth Product in Cipher's Growing Canadian Portfolio MISSISSAUGA, ON, April 5, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the Canadian launch of Beteflam™ (betamethasone valerate), a novel, patent-protected patch, indicated for the treatment of mild to moderate plaque psoriasis of the elbows and knees for a maximum duration of 30 days in adult patients1. "We're pleased to introduce Beteflam, a unique tr... 
Printer Friendly Version
03/04/16Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of U.S. Business
MISSISSAUGA, ON, March 4, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ralph Bohrer has joined the Company in the position of President and General Manager of its U.S. subsidiary. Mr. Bohrer is a seasoned pharmaceutical executive with 30 years of experience in sales and marketing leadership for growing dermatology companies. Prior to joining Cipher, he was Executive Director, Sales and Marketing of Taro Pharma, a glob... 
Printer Friendly Version
03/03/16Cipher Pharmaceuticals to Present at Two Upcoming Investor Conferences
MISSISSAUGA, ON, March 3, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming investor conferences. The 36th Annual Cowen and Company Health Care Conference in Boston on March 8, 2016 at 9:15 a.m. ET. The 28th Annual ROTH Conference in Orange County on Tuesday, March 15, 2016 at 3:30 p.m. PT. Both conference presentation... 
Printer Friendly Version
02/24/16Cipher Pharmaceuticals Reports 2015 Financial Results
Q4 revenue up 30%, Company significantly advances strategic plans to build a dermatology growth company MISSISSAUGA, ON, Feb. 24, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and twelve months ended December 31, 2015. "In 2015 we made major strides to transform Cipher from a royalty business into an integrated dermatology growth company with a solid commercial fou... 
Printer Friendly Version
02/22/16Cipher Pharmaceuticals Inc. announces Canadian launch of Actikerall™
MISSISSAUGA, ON, Feb. 22, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the Canadian launch of Actikerall™ (0.5% fluorouracil and 10% salicylic acid), indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients1. Actinic keratosis, also known as solar keratosis, is a skin condition caused... 
Printer Friendly Version
02/17/16Cipher Pharmaceuticals Launches a Foam Preparation of Bionect
- Offers Dermatologists a New Formulation of Leading Topical Product with Low Molecular Weight Hyaluronic Acid - - Bionect® Foam Improves Ease of Treatment Through an Advantageous Vehicle for Hard-to-Reach Dermal Ulcers, Wounds, Burns, and other Skin Conditions, Especially in Hair-Bearing Areas1 - CHARLESTON, S.C.--(BUSINESS WIRE)--Feb. 17, 2016-- Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that its prescr... 
Printer Friendly Version
02/16/16Cipher Pharmaceuticals Inc. announces Sitavig™ accepted for review by Health Canada
MISSISSAUGA, ON, Feb. 16, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Sitavig™ has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis (cold sores) in adults. "Cold sores are one of the most common viral skin infections, affecting one in five Canadians," said Shawn O'Brien, President and CEO o... 
Printer Friendly Version
02/09/16Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2015 Conference Call
MISSISSAUGA, ON, Feb. 9, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it will host a conference call for its Q4 and full-year 2015 financial results on Wednesday, February 24, 2016. Q4 AND YEAR-END 2015 CONFERENCE CALL WHEN: Wednesday, February 24, 2016 at 8:30AM ET CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through www.cipherpharma.com or http:/... 
Printer Friendly Version
02/09/16Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2015 Conference Call
MISSISSAUGA, ON, Feb. 9, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it will host a conference call for its Q4 and full-year 2015 financial results on Wednesday, February 24, 2016. Q4 AND YEAR-END 2015 CONFERENCE CALL WHEN: Wednesday, February 24, 2016 at 8:30AM ET CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through www.cipherpharma.... 
Printer Friendly Version
<< First | Previous | Next | Last >>